混合菌苗抗小鼠肝癌的初步研究  

The antitumor activity of a mixed bacterial vaccine against mousehepatoma

作　　者：冯学胜[1] 汤钊猷[1] 包卫华 

机构地区：[1]上海医科大学肝癌研究所

出　　处：《中国药学杂志》1995年第7期405-407,共3页Chinese Pharmaceutical Journal

基　　金：(美国)中华医学基金会93一585肝癌项目基金

摘　　要：混合菌苗（ＭＢｖ）是由化脓性链球菌和沙雷氏菌灭活制备的一种免疫调变剂。研究结果表明：（１）ＭＢＶ能明显延长腹水型肝癌小鼠的存活期（对照组１６．７±１．０ｄ，治疗组：腹腔应用者１８．５±１．０ｄ皮下应用者１８．８±１．５ｄ，Ｐ＜０．０５）和明显抑制皮下肝癌瘤块的生长（对照组２．３１０．７ｇ，治疗组：腹腔应用者１．９±０．２ｇ，皮下应用者１；７ｔ０．３ｇ，Ｐ＜０．０１）；（２）ＭＢＶ皮下应用后可明显提高肿瘤单个核细胞的浸润程度（对照组４１．５±８．６个／高倍键视野，治疗组：皮下应用者７４．３±１１。９个／高倍镜视野，Ｐ＜０．０ｌ），而腹腔应用却无此现象；（３）腹腔应用或皮下应用ＭＢＶ后，荷瘤小鼠的脾脏均明显增大（对照组０；２７±０．０５ｇ治疗组：皮下应用者０．３７±０．０５ｇ，腹腔应用者０．３５±０．０５ｇ，Ｐ＜０．０５）。上述观察提示，ＭＢＶ是一种有效的免疫刺激剂。Mixed bacterial vaccine(MBV),derived from heat-killer Streptococcic pyogenes andSerTatia marcescens,is a biological response modifier,In our study MBV prolonged the survival ofmice with ascitic hepatoma significantly,being 18.5±1.0 d(intraperitoneal injection,ip) and l8.8±1.5d( subcutaneous injection,sc)versus l6.7±1.Odas compared to the control,and suppressed the growth of subcutaneous nodule of hepatoma markedly,being 1.9±0.2 g(ip) and l.7+0.3g(sc)versus 2.3±0.7 g as compared to the control.Subcutaneous usage of MBV increasedthe infiItration of mononuclear cells into tumor,whereas intraperitoneal usage of MBV did not。Splenomegaly was observed after treatment of hepatoma bearing mice by using MBV either sub-cutaneously or intraperitoneally, The above data demonstrated that MBV is a potential immunostimulant, which could be used in tumor biotherapy。 These data also helped further elucidate themechanism of MBV against tumor。

关 键 词：混合菌苗 小鼠 抗癌作用 肝肿瘤 药理学 

分 类 号：R282.710.5[医药卫生—中药学]